ArticleBMJ open2019

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.

Y K Onno Teng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.